scispace - formally typeset
J

Javier A. Menendez

Researcher at NorthShore University HealthSystem

Publications -  336
Citations -  29348

Javier A. Menendez is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Cancer & Fatty acid synthase. The author has an hindex of 73, co-authored 317 publications receiving 25654 citations. Previous affiliations of Javier A. Menendez include Northwestern University & Boston Biomedical Research Institute.

Papers
More filters
Journal ArticleDOI

If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials

Alejandro Vazquez-Martin, +4 more
- 20 Nov 2009 - 
Journal ArticleDOI

Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.

Alejandro Vazquez-Martin, +7 more
- 01 Dec 2009 - 
TL;DR: Whether serum FASN (sFASN) could associate with circulating HER2 extracellular domain (HER2 ECD) in the blood of metastatic breast cancer patients and if quantitative determination of FASn molecules in blood could become a rapid and accurate non-invasive test to monitor disease progression and survival in HER2-overexpressing MBC undergoing Her2-targeted therapies is investigated.
Journal ArticleDOI

Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

Javier A. Menendez, +1 more
- 19 Oct 2007 - 
TL;DR: It appears that regardless of the mechanism that triggers the formation of oncogenic HER2/HER3 heterodimers (HER2 over-expression or overall low HER2 but high levels of the HER3 ligand heregulin), HER3 transphosphorylation is a common response of breast cancer cells upon treatment with current inhibitors of the Her receptor tyrosine kinase network.
Journal ArticleDOI

A bidirectional “αvβ3 integrin‐ERK1/ERK2 MAPK” connection regulates the proliferation of breast cancer cells

Luciano Vellon, +4 more
- 01 Oct 2006 - 
TL;DR: The results strongly suggest the existence of a bidirectional molecular connection αvβ3‐ERK1/ERK2 MAPK that would regulate breast cancer cells survival and proliferation.
Journal ArticleDOI

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Alejandro Vazquez-Martin, +5 more
- 01 Jan 2011 - 
TL;DR: These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2‐targeted drugs trastuzumab and lapatinib.